Metformin May Slow Cognitive Decline in Seniors With T2DM
WEDNESDAY, Sept. 23, 2020 -- For older adults with type 2 diabetes, cognitive decline is slower and dementia risk reduced for those receiving metformin, according to a study published online Sept. 23 in Diabetes Care.
Katherine Samaras, M.B.B.S., Ph.D., from the Garvan Institute of Medical Research in Darlinghurst, Australia, and colleagues conducted a prospective observational study of 1,037 community-dwelling older adults without dementia aged 70 to 90 years at baseline. Cognitive function was measured every two years, and a battery of tests measured executive function, memory, attention/speed, language, and visuospatial function. At baseline and two years, 526 participants underwent magnetic resonance imaging to measure total brain, hippocampal, and parahippocampal volumes.
The researchers found that 123 of the participants had diabetes and 67 of them received metformin. Compared with those with diabetes who were not receiving metformin, those receiving metformin had significantly slower global cognition and executive functional decline. Compared with those with diabetes receiving metformin, those with diabetes not receiving metformin had significantly higher incident dementia (odds ratio, 5.29).
"Randomized controlled studies are required to determine whether metformin may have a protective effect against dementia or cognitive decline, both in people with diabetes, and given metformin's long safety record, older people without diabetes," the authors write.
One author disclosed financial ties to the pharmaceutical industry.
© 2020 HealthDay. All rights reserved.
Posted: September 2020
Read this next
WEDNESDAY, Nov. 25, 2020 -- Apolipoprotein E4 (ApoE4) genotype, anxiety, and lower hippocampal (HV) and entorhinal cortex volumes (ERV) are associated with an elevated progression...
WEDNESDAY, Nov. 25, 2020 -- For older adults presenting to the emergency department with COVID-19, delirium is common and is associated with worse outcomes, according to a study...
WEDNESDAY, Nov. 25, 2020 -- Sotagliflozin is beneficial for the treatment of type 2 diabetes in patients with recent worsening heart failure as well as in patients with chronic...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.